FDMT logo

FDMT 4D Molecular Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$11.93
-0.18 (-1.52%)

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipel…

Price

No data yet.

Social Signal Score

54
5d
—
30d
50
2 mentions
—
60d
54
5 mentions
—
90d
58
8 mentions
—
news: 8

Analyst Ratings

14 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 2Sell 1Strong Sell 0
Avg price target$29.67+148.7%
Low $20Median $32High $37
Current Consensus

Revenue

$0.00-100.00%
$-977.0K$27.71M$56.40M$85.09M
Mar 2018Sep 2026

Analyst Estimates

FY2025
$-3.26
$-3.93–$-2.16
8 analysts
FY2026
$-4.16
$-4.32–$-4.04
8 analysts
FY2027
$-4.10
$-4.35–$-3.51
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
David H. Kirn
Sector
Healthcare
Industry
Biotechnology
Employees
196
Beta
2.91
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
0.67
www.4dmoleculartherapeutics.com